title: HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families.
abstract: We and others recently discovered HHLA2 as a new B7 family member and transmembrane and immunoglobulin domain containing 2 (TMIGD2) as one of its receptors. Based on a new study we propose that HHLA2 may represent a novel immunosuppressive mechanism within the tumor microenvironment and hence could be a target for cancer therapy. TMIGD2 may be another therapeutic target.
authors.affiliation: Department of Microbiology and Immunology; Albert Einstein College of Medicine ; Bronx, NY USA ; Department of Oncology; Montefiore Medical Center; Albert Einstein College of Medicine ; Bronx, NY USA.
authors.forename: Murali
authors.initials: M
authors.lastname: Janakiram
authors.affiliation: Department of Microbiology and Immunology; Albert Einstein College of Medicine ; Bronx, NY USA.
authors.forename: Jordan M
authors.initials: JM
authors.lastname: Chinai
authors.affiliation: Department of Obstetrics and Gynecology; Renji Hospital; Shanghai Jiao Tong University School of Medicine ; Shanghai, China.
authors.forename: Aimin
authors.initials: A
authors.lastname: Zhao
authors.affiliation: Department of Oncology; Montefiore Medical Center; Albert Einstein College of Medicine ; Bronx, NY USA.
authors.forename: Joseph A
authors.initials: JA
authors.lastname: Sparano
authors.affiliation: Department of Microbiology and Immunology; Albert Einstein College of Medicine ; Bronx, NY USA ; Department of Oncology; Montefiore Medical Center; Albert Einstein College of Medicine ; Bronx, NY USA.
authors.forename: Xingxing
authors.initials: X
authors.lastname: Zang
keywords: B7 family; CD28 family; HHLA2; TMIGD2; angiogenesis; immunosuppression; immunotherapy; ligand; receptor; tumor microenvironment